Home > Javier Cortes, ASCO20: Key findings of the KEYNOTE-355 study
Breast Cancer

Javier Cortes, ASCO20: Key findings of the KEYNOTE-355 study

Published Online: June 8th 2020

touchONCOLOGY were delighted to speak to Javier Cortes to discuss the key findings of the KEYNOTE-355 study, a randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.


1. What are the challenges in the treatment of triple-negative breast cancer? (0:06)

2. Could you tell us about the aims and design of the KEYNOTE-355 trial? (0:32)

3. What have we learned from the data emerging from this study? (1:10)

4. How can we predict which patients are most likely to respond to pembrolizumab? (3:00)

5. What will be the next steps in the clinical development of pembrolizumab for breast cancer? (4:05)


Speaker disclosure: Javier Cortes has received consulting/advisory fees from Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology and Boehringer Ingelheim. He has received honoraria from Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo. He has received research funding to his institution from Roche, Ariad pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer healthcare, Eisai, F.Hoffman-La Roche, Guardanth health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London. He has received stock, patents and intellectual property from MedSIR and travel, accommodation and expenses from Roche, Novartis, Eisai, pfizer and Daiichi Sankyo.

Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group.

Filmed in coverage of the 2020 ASCO Virtual Scientific Program.

Related Videos In Breast Cancer
  • Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar